EyeBio

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing and delivering new therapies to protect, restore, and improve vision for patients with sight-threatening eye diseases. Founded in 2021 by David Guyer, M.D., and Tony Adamis, M.D., EyeBio has a leadership team with a proven track record in ophthalmology drug development. The company's lead candidate, Restoret™, is a tri-specific Wnt agonist antibody designed to address unmet medical needs in patients with retinal vascular leakage, a known risk factor for diseases like diabetic macular edema (DME) and neovascular age-related macular degeneration (nvAMD).

EyeBio has successfully raised significant funding through its Series A financing, attracting investors like SV Health Investors, Samsara BioCapital, Jeito Capital, and MRL Ventures Fund. This funding allows the company to accelerate its clinical development program and expand its innovative retina pipeline. In 2024, Merck completed the acquisition of EyeBio, aiming to leverage EyeBio's expertise and advance the development of Restoret and other ongoing programs. This acquisition strengthens Merck's presence in ophthalmology and provides EyeBio with the resources to bring its promising therapies to patients worldwide.

EyeBio is a clinical-stage ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. They are focused on advancing a pipeline of ocular therapies that combine scientifically robust targets with innovative translational approaches.

EyeBio cultivates a collaborative and results-driven culture that prioritizes scientific innovation and the development of groundbreaking therapies for vision loss. The company values a diverse and inclusive team of experienced professionals who are passionate about improving patient outcomes and making a meaningful impact in the ophthalmology field. With a global presence and a strong emphasis on teamwork and open communication, EyeBio fosters an environment where individuals can thrive, learn, and contribute to the advancement of innovative treatments for serious eye diseases.